Biocon received approval for its complex drug-device combination Liraglutide (6mg/ml solution for injection in a pre-filled pen) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
The prioritization of medicines (PRIME) status has been granted to pegozafermin, a drug developed by 89bio for the non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
Healis Therapeutics, a company focused on neurotherapeutics, has recently announced its clinical collaboration with General Hospital (MGH) and Harvard Medical School (HMS) affiliates.
According to recent reports from Russian media, India emerged as the largest pharmaceutical supplier to Russia in 2023, replacing the previously dominant Western companies.
Indian pharmaceutical companies are currently focused on developing flagship products or mother brands. These are designed to incorporate various new combinations and ensure robust revenue growth and therapy leadership.
The National Institute of Mental Health and Neuro Sciences (NIMHANS) recently displayed Electroconvulsive, which is considered to be one of the earliest medical treatments that has shown reasonable effectiveness in treating severe
Dr. Kuldeep Sachdeva, President and Chief Medical Officer (CMO) of Molbio Diagnostics, has emphasized implementing national essential diagnostic guidelines in India to revolutionize healthcare delivery.
Intuitive medical device firm and the innovation leader in minimally invasive care has secured the US FDA endorsement for da Vinci 5, the organization's cutting-edge multiport robotic system. “We are pleased to receive...
Pharmaceutical and healthcare firm Sanofi announced an exclusive distribution with Cipla for their Central Nervous System (CNS) product line in India. Because of this partnership, Cipla will deal with disseminating Sanofi India's six CNS brands...
Astellas Pharma Inc., based in Tokyo, reported the other day Japan's Ministry of Health, Labour and Welfare approved VYLOYâ„¢ (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal neutralizer for patients with CLDN18.2 positive, unresectable...
, CDSCO.jpg)
